Tata Elxsi reported a mixed Q4 FY26 with revenue of ₹993.8 crore (+0.9% QoQ in constant currency) and EBITDA margin expanding 130 bps QoQ to 24.6%. Transportation & Mobility at 77% of revenue continues to hold up. The Healthcare & Life Sciences vertical remains a drag due to budget delays. FY27 guidance is higher single-digit revenue growth.
Key Financial Highlights — Q4 FY26
| Metric | Q4 FY26 | Notes |
|---|---|---|
| Revenue | ₹993.8 cr | +0.9% QoQ (Constant Currency) |
| EBITDA Margin | 24.6% | +130 bps QoQ |
| Utilization | 73% | — |
| Transportation Revenue Share | 77% | Dominant vertical |
| Currency Tailwind (Margin) | +155 bps | FX benefit |
| Salary Hike Impact (Margin) | -90 bps | Q4 FY26 |
| Operating Leverage (Margin) | +65 bps | — |
| FY27 Revenue Growth Guidance | Higher single-digit | — |
| Q4 FY27 PBT Margin Target | 27% | Exit target |
What Drove the Results
Transportation & Mobility holding the franchise. At 77% of revenue, the Transportation vertical — covering automotive OEMs, EV platforms, and connected mobility — remains Tata Elxsi's core strength. The company's embedded software and SDV (Software-Defined Vehicle) capabilities are in high demand as global auto OEMs accelerate digital transformation.
EBITDA margin improvement was currency-assisted. The 130 bps QoQ margin expansion breaks down as: currency tailwind +155 bps, salary hike impact -90 bps, operating leverage +65 bps. The underlying operational margin without currency benefit is roughly flat QoQ — an important nuance for FY27 projections if the currency tailwind reverses.
Healthcare & Life Sciences vertical is the key drag. Delayed budget decisions from macro uncertainty have slowed deal closures in this vertical. Management expects recovery as macro stabilises, but the timing is uncertain — this creates FY27 upside optionality if the vertical recovers.
Utilization at 73% signals capacity available for growth. With 73% utilization, Tata Elxsi has headroom to absorb new deals without significant headcount additions, protecting margins on deal ramp-ups.
According to NSE, Tata Elxsi is part of the Nifty IT index — the 10-stock IT sector benchmark. The company's specialisation in embedded engineering (vs IT services) gives it a differentiated position within this index.
What Management Said
Management acknowledged Q4 FY26 as a "holding quarter" — the franchise is stable, margins are improving, but growth acceleration requires Healthcare recovery and new deal ramp-ups in Transportation. The FY27 guidance of "higher single-digit growth" is conservative by design — reflecting caution on Healthcare timing.
On margins, management set a PBT target of 27% for Q4 FY27 exit — implying further improvement from the current 24.6% EBITDA level over four quarters. The currency tailwind may not be a permanent feature, so the underlying margin improvement path is important to watch.
Key Tailwinds and Risks
Tailwinds:
- SDV (Software-Defined Vehicles) transition is accelerating globally — Tata Elxsi is deeply embedded with OEMs in this shift
- Healthcare recovery is an upside option — delayed deals could convert in H1 FY27
- Currency tailwind if INR remains weaker (structural for USD-billed contracts)
- Utilization headroom means growth won't require proportional headcount cost
Risks:
- Transportation vertical concentration at 77% creates sector-specific risk if auto cycle turns down
- Healthcare & Life Sciences recovery timing is uncertain — could extend into H2 FY27
- Currency tailwind can reverse — underlying margin is roughly flat without FX support
- AI-led competition in embedded engineering and automotive software is growing
StockMirror AI Signal Summary
| Signal | Reading |
|---|---|
| Overall Sentiment | Mixed / Cautiously Positive |
| Management Confidence | High |
| Revenue Growth on Track | Partial — Transportation yes, Healthcare no |
| Earnings Quality | Impacted by currency tailwind (155 bps) — note in context |
| Margin Direction | Expansion (24.6%, +130 bps QoQ) |
| Outlook | Conservative guidance — upside if Healthcare recovers |
Full AI analysis including analyst Q&A at /TATAELXSI/earnings.
Tracking IT Services Stocks on StockMirror
Tata Elxsi is part of the Nifty IT index along with TCS, Infosys, Wipro, HCL Tech, and 5 others. If you want to compare how Tata Elxsi's margin trajectory compares to the broader IT sector in Q4 FY26, the StockMirror AI Analyst can run that comparison from actual transcript data.
Use the /screener to filter Nifty IT stocks by Margin Direction and Management Confidence side by side.
Key Takeaways
- Tata Elxsi Q4 FY26 revenue ₹993.8 cr — modest 0.9% QoQ CC growth, but EBITDA margin strong at 24.6%
- EBITDA expansion of 130 bps QoQ was partly currency-driven (+155 bps FX tailwind) — watch underlying trend
- Transportation & Mobility (77% of revenue) is holding up; Healthcare & Life Sciences is the overhang
- FY27 guidance: higher single-digit growth — conservative, with Healthcare recovery as upside option
- PBT margin target 27% at Q4 FY27 exit implies ~250 bps improvement from current levels over 4 quarters
FAQ
What were Tata Elxsi Q4 FY26 results? Revenue ₹993.8 crore (+0.9% QoQ CC), EBITDA margin 24.6% (+130 bps QoQ), utilization 73%, Transportation at 77% of revenue. Healthcare & Life Sciences remains weak due to budget delays.
What is Tata Elxsi's FY27 growth guidance? Higher single-digit revenue growth. PBT margin target is 27% at Q4 FY27 exit. Healthcare vertical recovery is the key variable.
Why is Tata Elxsi's Healthcare vertical weak? Delayed deal decisions from macro uncertainty and client budget freezes. Management expects recovery as budgets normalise, but timing is uncertain.
How does currency affect Tata Elxsi's margins? Q4 FY26 currency tailwind was +155 bps, salary hike impact was -90 bps, operating leverage +65 bps — net +130 bps QoQ margin expansion.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StockMirror AI analysis is based on earnings call transcripts. Always do your own research before making investment decisions.